Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 14;186(19):4038-4058.
doi: 10.1016/j.cell.2023.08.016. Epub 2023 Sep 6.

Menopause-Biology, consequences, supportive care, and therapeutic options

Affiliations
Free article
Review

Menopause-Biology, consequences, supportive care, and therapeutic options

Susan R Davis et al. Cell. .
Free article

Abstract

Menopause is the cessation of ovarian function, with loss of reproductive hormone production and irreversible loss of fertility. It is a natural part of reproductive aging. The physiology of the menopause is complex and incompletely understood. Globally, menopause occurs around the age of 49 years, with geographic and ethnic variation. The hormonal changes of the menopause transition may result in both symptoms and long-term systemic effects, predominantly adverse effects on cardiometabolic and musculoskeletal health. The most effective treatment for bothersome menopausal symptoms is evidence-based, menopausal hormone therapy (MHT), which reduces bone loss and may have cardiometabolic benefits. Evidence-based non-hormonal interventions are also available for symptom relief. Treatment should be individualized with shared decision-making. Most MHT regimens are not regulator approved for perimenopausal women. Studies that include perimenopausal women are needed to determine the efficacy and safety of treatment options. Further research is crucial to improve menopause care, along with research to guide policy and clinical practice.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.R.D. reports honoraria from Besins Healthcare, Mayne Pharma, Health Ed, BioSyent, Lawley Pharmaceuticals, and Que Oncology. She has served on advisory boards for Mayne Pharma, Astellas Pharmaceuticals, Theramex, and Gedeon Richter and has been an institutional investigator for Que Oncology and Ovoca Bio. J.P. is PI for a Multicentre Trial sponsored by Bayer, Fees to UVa, serves on the editorial board for OBG Management, and is an author for Up To Date and Merck. N.S. is a study investigator and member of the scientific advisory board and consultant for Astellas; is a member of the scientific advisory board for Amazon (Project Ember), MenoGeniX Inc., and Que Oncology; and is a consultant for Ansh Labs. She has served as the president of the Society for Reproductive Investigation in the past. T.S. has received consulting fees from Abbott, Astellas, Gedeon Richter, Mitsubishi Tanabe, Sojournix, Estetra, Mithra, Actavis, Medtronic, Shionogi, and Applied Medical and speaker’s honoraria from Abbott, Shionogi, Gedeon Richter, Intuitive Surgical, Applied Medical, Theramex.

Similar articles

Cited by

Publication types

LinkOut - more resources